Floatz logo

GEMOGENOVATUCEL-T

Connective Tissue Neoplasm

Gradalis, Inc.Cell therapyPhase 3Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Connective Tissue Neoplasm cohort.

Asset / SponsorPhaseRating
Irinotecan
Gradalis, Inc.
Phase 3B

Same molecule, other indications

GEMOGENOVATUCEL-T is also rated in:

ovarian cancerDormant
B
Indicative ·
57 / 100
View asset →
uterine cancerDormant
B
Indicative ·
57 / 100
View asset →
Ewing sarcomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →